Onkure Therapeutics Inc
onkuretherapeutics.comWhat Do They Do?
Develops small-molecule drug candidates targeting specific mutations in cancers and other diseases, including breast cancer and vascular malformations, for patients with those conditions.
10-K for FY2025, filed Mar 12, 2026OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery…View ↗
Our lead product candidate, OKI-219, is a highly selective inhibitor of PI3Kα harboring the H1047R mutation (“PI3KαH1047R”) that has a much…View ↗
Expand the development of PI3Ka inhibitors beyond breast cancer by harnessing the knowledge gained by our discovery team from understanding…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2024, filed Mar 10, 2025
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$15.3MView ↗
- ▼ 0% (Loss)
- vs −$15.4M in Q2 FY2025
From mitochondrial disease to mutation-targeted medicines
The earlier report described developing mavodelpar for rare genetic mitochondrial diseases. The latest report focuses on mutation-targeted drug candidates for cancers and other diseases, including breast cancer and vascular malformations.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 12, 2026
Who Do They Compete With?
Competes with Novartis, Astra Zeneca, Celcuity, Menarini, Totus Medicines, Relay Therapeutics, Scorpion Therapeutics, and Synnovation Therapeutics
10-K for FY2025, filed Mar 12, 2026There are multiple PI3Kα-pathway targeted agents either approved or under clinical development that may compete with OKI-219 and our…View ↗
Loading...
